Biotech company testing psilocybin pill requests preemptive change in Kansas law
A lobbyist requested House Bill 2218 on behalf of Compass Pathways… “This bill does not decriminalize or legalize psilocybin or any other psychedelic substance, nor does this bill allow access to drugs that have not been FDA-approved,” said Tess Bettler, a representative from Compass Pathways, in written testimony to the House health committee.
The bill would specifically legalize Compass Pathways’ drug, a 25 mg pill capsule called COMP 360, ensuring the company has a path to bringing the drug to Kansas doctors’ offices if it becomes FDA-approved. The proposed legislation would exempt any FDA-approved form of psilocybin from the state’s controlled substances act. “Unless and until an FDA-approved and DEA-rescheduled product is also rescheduled in Kansas, patients will not have access to it,” Bettler wrote.
Original Article (Kansas Law Reflector):
Biotech company testing psilocybin pill requests preemptive change in Kansas law
Artwork Fair Use: Hannes Grobe
Recent Comments